Click to Enlarge Market Cap: $65M
Description from Yahoo! Finance
Agenus (NASDAQ:AGEN), a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. It offers oncophage vaccine for the treatment of adjuvant renal cell carcinoma.
Click to Enlarge Technical Analysis
The stock trades both above its 200- and 50-day moving averages and is consolidating above $3. A move above $3.50 could swing the stock much higher while a close below $2 puts the stock in danger of filling at least part of the gap dating back to September 2011 (gray box).